| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotics | 89 | 2020 | 124 | 19.640 |
Why?
|
| Nephrectomy | 62 | 2020 | 123 | 14.800 |
Why?
|
| Laparoscopy | 68 | 2018 | 174 | 14.680 |
Why?
|
| Kidney Neoplasms | 49 | 2020 | 200 | 11.850 |
Why?
|
| Cystectomy | 44 | 2020 | 105 | 9.730 |
Why?
|
| Urinary Bladder Neoplasms | 37 | 2020 | 192 | 7.240 |
Why?
|
| Urologic Surgical Procedures | 28 | 2019 | 64 | 6.380 |
Why?
|
| Prostatectomy | 29 | 2019 | 83 | 6.200 |
Why?
|
| Carcinoma, Transitional Cell | 20 | 2018 | 69 | 5.160 |
Why?
|
| Ureter | 18 | 2018 | 38 | 4.670 |
Why?
|
| Indocyanine Green | 10 | 2019 | 13 | 4.080 |
Why?
|
| Prostatic Neoplasms | 29 | 2019 | 470 | 3.430 |
Why?
|
| Postoperative Complications | 34 | 2019 | 785 | 3.170 |
Why?
|
| Kidney Pelvis | 13 | 2018 | 17 | 3.160 |
Why?
|
| Ureteral Neoplasms | 8 | 2015 | 11 | 3.030 |
Why?
|
| Ureteral Obstruction | 12 | 2013 | 28 | 3.020 |
Why?
|
| Humans | 214 | 2020 | 32024 | 3.020 |
Why?
|
| Urinary Bladder | 13 | 2018 | 182 | 2.970 |
Why?
|
| Male | 163 | 2020 | 19195 | 2.870 |
Why?
|
| Coloring Agents | 7 | 2019 | 29 | 2.790 |
Why?
|
| Carcinoma, Renal Cell | 11 | 2019 | 114 | 2.740 |
Why?
|
| Middle Aged | 119 | 2020 | 11868 | 2.550 |
Why?
|
| Aged | 99 | 2020 | 10340 | 2.420 |
Why?
|
| Treatment Outcome | 71 | 2020 | 3317 | 2.310 |
Why?
|
| Lymph Node Excision | 16 | 2018 | 90 | 2.240 |
Why?
|
| Female | 127 | 2020 | 19953 | 2.230 |
Why?
|
| Surgery, Computer-Assisted | 9 | 2019 | 53 | 2.200 |
Why?
|
| Kidney Calculi | 10 | 2018 | 23 | 2.170 |
Why?
|
| Urinary Diversion | 12 | 2020 | 26 | 2.120 |
Why?
|
| Adult | 81 | 2019 | 9366 | 2.000 |
Why?
|
| Kidney | 15 | 2019 | 515 | 1.760 |
Why?
|
| Prostatic Hyperplasia | 5 | 2019 | 44 | 1.650 |
Why?
|
| Aged, 80 and over | 36 | 2019 | 4000 | 1.580 |
Why?
|
| Retrospective Studies | 48 | 2020 | 3523 | 1.570 |
Why?
|
| Reconstructive Surgical Procedures | 8 | 2012 | 199 | 1.550 |
Why?
|
| Retroperitoneal Space | 12 | 2018 | 20 | 1.330 |
Why?
|
| Adrenalectomy | 7 | 2016 | 30 | 1.300 |
Why?
|
| Prospective Studies | 25 | 2019 | 2283 | 1.280 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2019 | 288 | 1.220 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 194 | 1.190 |
Why?
|
| Follow-Up Studies | 30 | 2019 | 2280 | 1.180 |
Why?
|
| Adrenal Gland Neoplasms | 5 | 2016 | 15 | 1.170 |
Why?
|
| Glomerular Filtration Rate | 17 | 2020 | 305 | 1.120 |
Why?
|
| Length of Stay | 16 | 2019 | 318 | 1.100 |
Why?
|
| Ureteral Calculi | 4 | 2018 | 7 | 1.080 |
Why?
|
| Lymphography | 3 | 2014 | 4 | 1.070 |
Why?
|
| Nomograms | 4 | 2020 | 32 | 1.030 |
Why?
|
| Ureteral Diseases | 4 | 2018 | 8 | 1.000 |
Why?
|
| Angiography | 2 | 2014 | 80 | 0.920 |
Why?
|
| Young Adult | 19 | 2019 | 2615 | 0.900 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 170 | 0.880 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 154 | 0.850 |
Why?
|
| Feasibility Studies | 16 | 2019 | 292 | 0.830 |
Why?
|
| Neoplasm Staging | 15 | 2018 | 456 | 0.830 |
Why?
|
| Warm Ischemia | 5 | 2020 | 9 | 0.780 |
Why?
|
| Sutures | 2 | 2011 | 20 | 0.780 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2009 | 82 | 0.780 |
Why?
|
| Replantation | 2 | 2013 | 10 | 0.780 |
Why?
|
| Urinary Bladder Fistula | 2 | 2012 | 2 | 0.760 |
Why?
|
| Fistula | 2 | 2012 | 11 | 0.750 |
Why?
|
| Fluorescence | 7 | 2016 | 20 | 0.740 |
Why?
|
| Adolescent | 22 | 2019 | 3526 | 0.740 |
Why?
|
| Pelvis | 9 | 2018 | 61 | 0.730 |
Why?
|
| Pheochromocytoma | 3 | 2013 | 6 | 0.730 |
Why?
|
| Patient Positioning | 4 | 2015 | 23 | 0.730 |
Why?
|
| Urologic Neoplasms | 3 | 2019 | 14 | 0.700 |
Why?
|
| Stents | 5 | 2018 | 178 | 0.700 |
Why?
|
| Vesicovaginal Fistula | 3 | 2010 | 5 | 0.690 |
Why?
|
| Prostate | 8 | 2013 | 67 | 0.670 |
Why?
|
| Penile Neoplasms | 1 | 2019 | 6 | 0.660 |
Why?
|
| Urologic Diseases | 1 | 2019 | 27 | 0.650 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 42 | 0.650 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 311 | 0.640 |
Why?
|
| Surgical Instruments | 5 | 2012 | 24 | 0.630 |
Why?
|
| Urogenital Surgical Procedures | 2 | 2009 | 7 | 0.610 |
Why?
|
| Kidney Diseases | 5 | 2016 | 249 | 0.610 |
Why?
|
| Lymph Nodes | 5 | 2014 | 106 | 0.610 |
Why?
|
| Renal Artery | 6 | 2019 | 47 | 0.600 |
Why?
|
| Kidney Diseases, Cystic | 3 | 2018 | 13 | 0.600 |
Why?
|
| Child | 16 | 2016 | 2441 | 0.580 |
Why?
|
| Hemostasis, Surgical | 1 | 2016 | 13 | 0.560 |
Why?
|
| Risk Factors | 18 | 2019 | 3869 | 0.550 |
Why?
|
| Urinary Tract | 2 | 2015 | 22 | 0.540 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 49 | 0.530 |
Why?
|
| Blood Loss, Surgical | 6 | 2018 | 49 | 0.530 |
Why?
|
| Proteinuria | 1 | 2016 | 59 | 0.530 |
Why?
|
| Ureterostomy | 3 | 2010 | 4 | 0.520 |
Why?
|
| Urinary Catheterization | 1 | 2015 | 16 | 0.510 |
Why?
|
| Time Factors | 12 | 2019 | 2152 | 0.510 |
Why?
|
| Ureteroscopy | 3 | 2006 | 6 | 0.500 |
Why?
|
| Hysterectomy | 4 | 2009 | 45 | 0.490 |
Why?
|
| Perioperative Care | 5 | 2018 | 59 | 0.490 |
Why?
|
| Sarcopenia | 1 | 2015 | 64 | 0.490 |
Why?
|
| Preoperative Period | 5 | 2019 | 35 | 0.480 |
Why?
|
| Clinical Competence | 4 | 2013 | 333 | 0.480 |
Why?
|
| Prognosis | 11 | 2018 | 1505 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 370 | 0.460 |
Why?
|
| Cystostomy | 2 | 2012 | 5 | 0.460 |
Why?
|
| Infrared Rays | 2 | 2016 | 18 | 0.460 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 10 | 0.450 |
Why?
|
| Survival Rate | 8 | 2019 | 885 | 0.450 |
Why?
|
| Urethra | 4 | 2011 | 102 | 0.450 |
Why?
|
| Patient Selection | 7 | 2019 | 277 | 0.440 |
Why?
|
| Program Evaluation | 2 | 2011 | 186 | 0.440 |
Why?
|
| Lymphocytes | 1 | 2013 | 57 | 0.440 |
Why?
|
| Adenoma | 1 | 2013 | 35 | 0.440 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2013 | 20 | 0.440 |
Why?
|
| Kidney Transplantation | 3 | 2015 | 517 | 0.430 |
Why?
|
| Neutrophils | 1 | 2013 | 112 | 0.430 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 144 | 0.420 |
Why?
|
| Uterine Cervical Diseases | 1 | 2012 | 2 | 0.420 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 878 | 0.420 |
Why?
|
| Constriction | 7 | 2019 | 13 | 0.410 |
Why?
|
| Erectile Dysfunction | 2 | 2018 | 51 | 0.410 |
Why?
|
| Uremia | 2 | 2011 | 9 | 0.400 |
Why?
|
| Wound Healing | 2 | 2010 | 185 | 0.400 |
Why?
|
| Suture Techniques | 1 | 2011 | 61 | 0.390 |
Why?
|
| Intraoperative Care | 1 | 2011 | 48 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 541 | 0.380 |
Why?
|
| Nephrostomy, Percutaneous | 7 | 2016 | 17 | 0.380 |
Why?
|
| Risk Assessment | 11 | 2019 | 1435 | 0.380 |
Why?
|
| Cesarean Section | 1 | 2012 | 112 | 0.380 |
Why?
|
| Peritoneum | 3 | 2018 | 33 | 0.370 |
Why?
|
| Mononeuropathies | 1 | 2010 | 2 | 0.370 |
Why?
|
| Cystoscopy | 4 | 2014 | 27 | 0.370 |
Why?
|
| Urothelium | 1 | 2011 | 55 | 0.370 |
Why?
|
| Postoperative Period | 4 | 2019 | 97 | 0.360 |
Why?
|
| Urinary Bladder Calculi | 1 | 2010 | 2 | 0.360 |
Why?
|
| Forecasting | 5 | 2019 | 144 | 0.360 |
Why?
|
| Urinary Fistula | 1 | 2009 | 2 | 0.350 |
Why?
|
| Disease Progression | 4 | 2017 | 594 | 0.350 |
Why?
|
| Penis | 2 | 2010 | 35 | 0.350 |
Why?
|
| Pyonephrosis | 1 | 2009 | 1 | 0.350 |
Why?
|
| Drainage | 3 | 2016 | 72 | 0.340 |
Why?
|
| Lower Extremity | 1 | 2010 | 100 | 0.340 |
Why?
|
| Survival Analysis | 5 | 2018 | 488 | 0.340 |
Why?
|
| Urogenital System | 1 | 2009 | 9 | 0.340 |
Why?
|
| Uterine Diseases | 1 | 2009 | 20 | 0.340 |
Why?
|
| Intraoperative Complications | 3 | 2019 | 56 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2019 | 1831 | 0.320 |
Why?
|
| Equipment Design | 5 | 2011 | 172 | 0.320 |
Why?
|
| Databases, Factual | 6 | 2019 | 355 | 0.320 |
Why?
|
| Urinary Incontinence | 2 | 2019 | 47 | 0.310 |
Why?
|
| Lithotripsy | 5 | 2007 | 11 | 0.310 |
Why?
|
| Exosomes | 2 | 2019 | 43 | 0.310 |
Why?
|
| Vena Cava, Inferior | 3 | 2019 | 32 | 0.300 |
Why?
|
| Anastomosis, Surgical | 4 | 2011 | 61 | 0.300 |
Why?
|
| Propensity Score | 5 | 2020 | 39 | 0.300 |
Why?
|
| Granuloma, Foreign-Body | 2 | 2010 | 7 | 0.300 |
Why?
|
| Ischemia | 4 | 2019 | 98 | 0.290 |
Why?
|
| Lymphangioma | 1 | 2006 | 7 | 0.280 |
Why?
|
| Urachus | 1 | 2006 | 3 | 0.270 |
Why?
|
| Postoperative Care | 6 | 2018 | 76 | 0.270 |
Why?
|
| Kidney Calices | 1 | 2006 | 4 | 0.270 |
Why?
|
| Carcinoma | 2 | 2004 | 92 | 0.270 |
Why?
|
| Penile Erection | 1 | 2005 | 21 | 0.260 |
Why?
|
| Urography | 4 | 2009 | 15 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 900 | 0.250 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 687 | 0.250 |
Why?
|
| Logistic Models | 5 | 2019 | 781 | 0.250 |
Why?
|
| Preoperative Care | 4 | 2016 | 115 | 0.250 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2004 | 2 | 0.240 |
Why?
|
| Epididymis | 1 | 2004 | 9 | 0.240 |
Why?
|
| Comorbidity | 2 | 2017 | 569 | 0.240 |
Why?
|
| Age Factors | 3 | 2018 | 1194 | 0.240 |
Why?
|
| Infertility, Male | 1 | 2004 | 24 | 0.230 |
Why?
|
| Iliac Vein | 1 | 2004 | 8 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 5 | 2008 | 61 | 0.230 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 245 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Apolipoproteins | 2 | 2016 | 200 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 757 | 0.220 |
Why?
|
| Renal Insufficiency | 3 | 2019 | 58 | 0.220 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 251 | 0.220 |
Why?
|
| Vascular Surgical Procedures | 1 | 2004 | 90 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Adrenal Glands | 1 | 2002 | 4 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 79 | 0.210 |
Why?
|
| ROC Curve | 4 | 2019 | 167 | 0.210 |
Why?
|
| Renal Veins | 3 | 2016 | 7 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 319 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2009 | 1324 | 0.200 |
Why?
|
| Radiography | 2 | 2015 | 377 | 0.200 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 594 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 518 | 0.200 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 638 | 0.200 |
Why?
|
| Candidiasis | 1 | 2020 | 5 | 0.190 |
Why?
|
| Pyelonephritis | 1 | 2020 | 9 | 0.190 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 12 | 0.180 |
Why?
|
| Emphysema | 1 | 2020 | 12 | 0.180 |
Why?
|
| United States | 6 | 2019 | 3938 | 0.180 |
Why?
|
| Urology | 1 | 2020 | 31 | 0.180 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 7 | 0.170 |
Why?
|
| Qa-SNARE Proteins | 1 | 2019 | 6 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 67 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 192 | 0.160 |
Why?
|
| Thrombosis | 1 | 2019 | 73 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 21 | 0.160 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 21 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 20 | 0.150 |
Why?
|
| Endoscopy | 1 | 2018 | 57 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 38 | 0.150 |
Why?
|
| Costs and Cost Analysis | 2 | 2009 | 100 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 607 | 0.150 |
Why?
|
| Reoperation | 4 | 2019 | 227 | 0.150 |
Why?
|
| Incidence | 4 | 2019 | 1200 | 0.150 |
Why?
|
| Placenta | 1 | 2018 | 74 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 128 | 0.150 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 106 | 0.140 |
Why?
|
| Laparoscopes | 2 | 2009 | 3 | 0.140 |
Why?
|
| Probability | 3 | 2007 | 158 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Intraoperative Period | 1 | 2016 | 42 | 0.140 |
Why?
|
| Protective Agents | 1 | 2016 | 4 | 0.140 |
Why?
|
| Organ Size | 2 | 2015 | 210 | 0.140 |
Why?
|
| India | 5 | 2008 | 61 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2017 | 136 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2016 | 182 | 0.130 |
Why?
|
| Urinary Calculi | 2 | 2006 | 7 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 273 | 0.130 |
Why?
|
| Hypertension | 3 | 2019 | 957 | 0.130 |
Why?
|
| Psoas Muscles | 1 | 2015 | 19 | 0.130 |
Why?
|
| North Carolina | 2 | 2016 | 1516 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2018 | 897 | 0.130 |
Why?
|
| Recurrence | 4 | 2010 | 265 | 0.130 |
Why?
|
| Stem Cells | 1 | 2018 | 313 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2016 | 526 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 319 | 0.120 |
Why?
|
| Creatinine | 2 | 2013 | 195 | 0.120 |
Why?
|
| Premedication | 1 | 2014 | 13 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 411 | 0.120 |
Why?
|
| Mesangial Cells | 1 | 2014 | 10 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 765 | 0.120 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 30 | 0.120 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 40 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2013 | 464 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 47 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 19 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 25 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.110 |
Why?
|
| Epinephrine | 1 | 2013 | 40 | 0.110 |
Why?
|
| Hyperplasia | 1 | 2013 | 38 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2010 | 565 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2013 | 544 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 46 | 0.110 |
Why?
|
| Dissection | 1 | 2012 | 17 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2014 | 508 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2016 | 923 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 46 | 0.100 |
Why?
|
| Europe | 3 | 2019 | 83 | 0.100 |
Why?
|
| Patient Readmission | 3 | 2019 | 125 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 105 | 0.100 |
Why?
|
| Dioxanes | 1 | 2011 | 6 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 1179 | 0.100 |
Why?
|
| African Americans | 1 | 2018 | 1428 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 131 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 918 | 0.090 |
Why?
|
| Ablation Techniques | 1 | 2011 | 26 | 0.090 |
Why?
|
| Biopsy | 4 | 2014 | 260 | 0.090 |
Why?
|
| Polyesters | 1 | 2011 | 76 | 0.090 |
Why?
|
| Polymers | 1 | 2011 | 64 | 0.090 |
Why?
|
| Operating Rooms | 1 | 2011 | 35 | 0.090 |
Why?
|
| Mineral Oil | 1 | 2010 | 4 | 0.090 |
Why?
|
| Sclerosis | 1 | 2010 | 10 | 0.090 |
Why?
|
| Physicians | 1 | 2013 | 158 | 0.090 |
Why?
|
| Ganglioneuroma | 1 | 2010 | 2 | 0.090 |
Why?
|
| Paraganglioma | 1 | 2010 | 5 | 0.090 |
Why?
|
| Urolithiasis | 2 | 2007 | 7 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2010 | 16 | 0.090 |
Why?
|
| Cystotomy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 18 | 0.090 |
Why?
|
| Algorithms | 2 | 2011 | 496 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2010 | 67 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2010 | 25 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 186 | 0.090 |
Why?
|
| Mesocolon | 1 | 2009 | 1 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2007 | 351 | 0.080 |
Why?
|
| Vaginal Fistula | 1 | 2008 | 2 | 0.080 |
Why?
|
| Biopsy, Needle | 3 | 2005 | 95 | 0.080 |
Why?
|
| Tissue Adhesions | 1 | 2008 | 9 | 0.080 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2009 | 47 | 0.080 |
Why?
|
| Nephrons | 2 | 2018 | 10 | 0.080 |
Why?
|
| Retreatment | 1 | 2008 | 41 | 0.080 |
Why?
|
| Anesthesia | 1 | 2009 | 64 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2008 | 31 | 0.080 |
Why?
|
| Animals | 4 | 2018 | 7466 | 0.080 |
Why?
|
| Seminal Vesicles | 2 | 2005 | 3 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 11 | 0.080 |
Why?
|
| Developing Countries | 1 | 2008 | 48 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 96 | 0.070 |
Why?
|
| Citric Acid | 2 | 2005 | 6 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2008 | 65 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 52 | 0.070 |
Why?
|
| Republic of Korea | 2 | 2019 | 12 | 0.070 |
Why?
|
| Carboplatin | 1 | 2007 | 48 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2007 | 67 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 82 | 0.070 |
Why?
|
| Punctures | 1 | 2006 | 33 | 0.070 |
Why?
|
| Models, Economic | 1 | 2006 | 20 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 725 | 0.070 |
Why?
|
| Analgesics | 1 | 2007 | 109 | 0.070 |
Why?
|
| Citrates | 1 | 2006 | 5 | 0.070 |
Why?
|
| Urogenital Abnormalities | 1 | 2006 | 3 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2006 | 21 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2006 | 53 | 0.070 |
Why?
|
| Flank Pain | 1 | 2005 | 1 | 0.070 |
Why?
|
| Software | 1 | 2006 | 127 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 261 | 0.070 |
Why?
|
| Adrenal Gland Diseases | 1 | 2005 | 1 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2007 | 179 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2016 | 1269 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2004 | 12 | 0.060 |
Why?
|
| Flutamide | 1 | 2004 | 5 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 532 | 0.060 |
Why?
|
| Quality of Life | 1 | 2011 | 932 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 39 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 288 | 0.060 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2004 | 3 | 0.060 |
Why?
|
| Creatine | 1 | 2003 | 5 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2004 | 23 | 0.060 |
Why?
|
| Protons | 1 | 2003 | 23 | 0.060 |
Why?
|
| Choline | 1 | 2003 | 14 | 0.060 |
Why?
|
| Vagina | 1 | 2004 | 57 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 474 | 0.060 |
Why?
|
| Uterus | 1 | 2004 | 93 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 1017 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2016 | 833 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 461 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2002 | 5 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 70 | 0.050 |
Why?
|
| Pregnancy | 2 | 2018 | 994 | 0.050 |
Why?
|
| Physical Examination | 2 | 2016 | 92 | 0.050 |
Why?
|
| Unnecessary Procedures | 1 | 2002 | 16 | 0.050 |
Why?
|
| Swine | 2 | 2016 | 215 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 253 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 15 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2020 | 82 | 0.050 |
Why?
|
| Fear | 1 | 2020 | 48 | 0.040 |
Why?
|
| Muscles | 1 | 2020 | 62 | 0.040 |
Why?
|
| Ohio | 1 | 2019 | 58 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 104 | 0.040 |
Why?
|
| Retrospective Moral Judgment | 1 | 2018 | 1 | 0.040 |
Why?
|
| Demography | 2 | 2010 | 110 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2018 | 9 | 0.040 |
Why?
|
| JC Virus | 1 | 2018 | 20 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Infant | 2 | 2016 | 1061 | 0.040 |
Why?
|
| Urodynamics | 1 | 2018 | 37 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 132 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 449 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2019 | 177 | 0.040 |
Why?
|
| International Cooperation | 1 | 2017 | 28 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 200 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2017 | 19 | 0.040 |
Why?
|
| Quality Control | 1 | 2017 | 44 | 0.040 |
Why?
|
| Cell Survival | 1 | 2018 | 286 | 0.040 |
Why?
|
| Overweight | 1 | 2019 | 279 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2018 | 397 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 734 | 0.040 |
Why?
|
| Lipids | 1 | 2018 | 229 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 217 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 163 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 663 | 0.030 |
Why?
|
| Magnesium Compounds | 2 | 2005 | 2 | 0.030 |
Why?
|
| Calcium Oxalate | 2 | 2005 | 3 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 599 | 0.030 |
Why?
|
| Phosphates | 2 | 2005 | 25 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2016 | 363 | 0.030 |
Why?
|
| Uric Acid | 2 | 2005 | 27 | 0.030 |
Why?
|
| Fascia | 2 | 2005 | 10 | 0.030 |
Why?
|
| Podocytes | 1 | 2014 | 20 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 155 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 88 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 687 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 494 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 142 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 435 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 19 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2012 | 10 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 230 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2012 | 9 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 181 | 0.030 |
Why?
|
| Reference Values | 1 | 2012 | 247 | 0.030 |
Why?
|
| Laos | 1 | 2010 | 3 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 4 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 312 | 0.020 |
Why?
|
| Men's Health | 1 | 2010 | 11 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 407 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 53 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 15 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 286 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 207 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 60 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2006 | 108 | 0.020 |
Why?
|
| Financing, Organized | 1 | 2005 | 14 | 0.020 |
Why?
|
| Professional Practice | 1 | 2005 | 24 | 0.020 |
Why?
|
| Apatites | 1 | 2005 | 1 | 0.020 |
Why?
|
| Powder Diffraction | 1 | 2005 | 2 | 0.020 |
Why?
|
| Convalescence | 1 | 2004 | 2 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2005 | 40 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2005 | 90 | 0.020 |
Why?
|
| Education, Medical | 1 | 2005 | 69 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2004 | 48 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 111 | 0.010 |
Why?
|
| Ileum | 1 | 2004 | 17 | 0.010 |
Why?
|
| Michigan | 1 | 2003 | 3 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 198 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 307 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 409 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2002 | 76 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 379 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 1530 | 0.010 |
Why?
|
| Registries | 1 | 2002 | 298 | 0.010 |
Why?
|
| Mass Screening | 1 | 2003 | 264 | 0.010 |
Why?
|